Reply: The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from Sputum.
作者信息
Kang Cheol-In
机构信息
Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
出版信息
Infect Chemother. 2021 Sep;53(3):565-567. doi: 10.3947/ic.2021.0306. Epub 2021 Sep 6.
Abstract
摘要
相似文献
1
Reply: The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from Sputum.回复：β-内酰胺酶抑制剂复合青霉素或头孢美唑对从痰液中分离出产超广谱β-内酰胺酶细菌的肺炎的疗效。
Infect Chemother. 2021 Sep;53(3):565-567. doi: 10.3947/ic.2021.0306. Epub 2021 Sep 6.
2
The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from Sputum.含β-内酰胺酶抑制剂的青霉素类或头孢美唑对从痰液中分离出产超广谱β-内酰胺酶细菌的肺炎的疗效。
Infect Chemother. 2021 Sep;53(3):562-564. doi: 10.3947/ic.2021.0065. Epub 2021 Sep 6.
3
Isolation of ESBL-producing Bacteria from Sputum in Community-acquired Pneumonia or Healthcare-associated Pneumonia Does Not Indicate the Need for Antibiotics with Activity against This Class.从社区获得性肺炎或医疗保健相关肺炎患者痰液中分离出产超广谱β-内酰胺酶（ESBL）细菌并不表明需要使用对这类细菌有活性的抗生素。
Intern Med. 2018 Feb 15;57(4):487-495. doi: 10.2169/internalmedicine.8867-17. Epub 2017 Oct 11.
4
Cefmetazole for extended-spectrum β-lactamase-producing Enterobacteriaceae in pediatric pyelonephritis.头孢美唑用于治疗小儿肾盂肾炎中产超广谱β-内酰胺酶肠杆菌科细菌感染
Pediatr Int. 2019 Jun;61(6):572-577. doi: 10.1111/ped.13847. Epub 2019 Jun 11.
5
In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae.头孢美唑和氟氧头孢对产超广谱β-内酰胺酶及质粒介导AmpCβ-内酰胺酶肠杆菌科细菌的体外活性及检测性能
Diagn Microbiol Infect Dis. 2016 Apr;84(4):322-7. doi: 10.1016/j.diagmicrobio.2015.12.001. Epub 2015 Dec 11.
6
The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.头孢美唑治疗产超广谱β-内酰胺酶肠杆菌科引起的肾盂肾炎的疗效。
Int J Infect Dis. 2013 Mar;17(3):e159-63. doi: 10.1016/j.ijid.2012.09.010. Epub 2012 Nov 8.
7
To Use, or Not to Use Carbapenem When Extended-spectrum β-lactamase (ESBL)-producing Bacteria Are Isolated from Sputum Cultures, That Is the Question.当从痰液培养中分离出产超广谱β-内酰胺酶（ESBL）的细菌时，是否使用碳青霉烯类药物，这是个问题。
Intern Med. 2018 Feb 15;57(4):455-456. doi: 10.2169/internalmedicine.9413-17. Epub 2017 Dec 21.
8
Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.产超广谱β-内酰胺酶大肠埃希菌引起的儿童社区获得性上尿路感染增加及氟氧头孢和头孢美唑的疗效。
Clin Exp Nephrol. 2019 Nov;23(11):1306-1314. doi: 10.1007/s10157-019-01775-w. Epub 2019 Aug 19.
9
Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.头孢美唑用于治疗产超广谱β-内酰胺酶肠杆菌科细菌所致菌血症并与碳青霉烯类药物比较
BMC Infect Dis. 2016 Aug 18;16(1):427. doi: 10.1186/s12879-016-1770-1.
10
[Evaluation of Antibiotics for the Treatment of Bacteremia Due to Extended-spectrum β-Lactamase-producing Escherichia coli].[用于治疗产超广谱β-内酰胺酶大肠埃希菌所致菌血症的抗生素评估]
Yakugaku Zasshi. 2015;135(6):829-33. doi: 10.1248/yakushi.14-00253.
本文引用的文献
1
The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from Sputum.含β-内酰胺酶抑制剂的青霉素类或头孢美唑对从痰液中分离出产超广谱β-内酰胺酶细菌的肺炎的疗效。
Infect Chemother. 2021 Sep;53(3):562-564. doi: 10.3947/ic.2021.0065. Epub 2021 Sep 6.
2
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会关于治疗产超广谱β-内酰胺酶肠杆菌科（ESBL-E）、碳青霉烯类耐药肠杆菌科（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的指导意见。
Clin Infect Dis. 2021 Apr 8;72(7):1109-1116. doi: 10.1093/cid/ciab295.
3
New treatment options for multiresistant gram negatives.多药耐药革兰氏阴性菌的新治疗选择。
Curr Opin Infect Dis. 2020 Apr;33(2):214-223. doi: 10.1097/QCO.0000000000000627.
4
Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.产超广谱β-内酰胺酶肠杆菌科细菌：碳青霉烯类药物节约选择。
Expert Rev Anti Infect Ther. 2019 Dec;17(12):969-981. doi: 10.1080/14787210.2019.1693258. Epub 2019 Nov 20.
5
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.哌拉西林-他唑巴坦与美罗培南对产 ESBLs 的大肠埃希菌或肺炎克雷伯菌血流感染且对头孢曲松耐药患者 30 天死亡率的影响：一项随机临床试验。
JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163.
6
Carbapenem-Sparing Therapy for Extended-Spectrum β-Lactamase-Producing E coli and Klebsiella pneumoniae Bloodstream Infection: The Search Continues.用于产超广谱β-内酰胺酶的大肠埃希菌和肺炎克雷伯菌血流感染的碳青霉烯类药物节省疗法：探索仍在继续。
JAMA. 2018 Sep 11;320(10):979-981. doi: 10.1001/jama.2018.12565.
7
Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.碳青霉烯类与其他抗生素治疗产 ESBL 肠杆菌科菌血症的临床疗效比较：系统评价和荟萃分析。
J Antimicrob Chemother. 2018 Oct 1;73(10):2631-2642. doi: 10.1093/jac/dky168.
8
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.非碳青霉烯类β-内酰胺类药物在治疗产超广谱β-内酰胺酶感染中的应用
Clin Infect Dis. 2017 Apr 1;64(7):972-980. doi: 10.1093/cid/cix034.
9
Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.哌拉西林-他唑巴坦作为产超广谱β-内酰胺酶的大肠埃希菌和肺炎克雷伯菌所致菌血症的初始经验性治疗药物。
J Infect. 2012 May;64(5):533-4. doi: 10.1016/j.jinf.2012.01.008. Epub 2012 Jan 16.
10
β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.β-内酰胺/β-内酰胺抑制剂联合治疗产超广谱β-内酰胺酶大肠埃希菌菌血症：前瞻性队列的事后分析。
Clin Infect Dis. 2012 Jan 15;54(2):167-74. doi: 10.1093/cid/cir790. Epub 2011 Nov 4.
Zotero 插件